Why is creatine kinase markedly elevated in a young boy with Duchenne muscular dystrophy, and how should it be used for diagnosis and monitoring?

Creatine Kinase Elevation in Duchenne Muscular Dystrophy

Why CK is Markedly Elevated

Creatine kinase is markedly elevated in Duchenne muscular dystrophy because the absence of dystrophin protein causes muscle cell membrane instability, leading to continuous mechanical stress-induced damage during muscle contraction and persistent leakage of intracellular CK into the bloodstream. 1

The pathophysiology involves:

• Dystrophin normally links the intracellular cytoskeleton to the extracellular matrix through the dystrophin-associated protein complex, providing mechanical stability during contraction. 1 Without functional dystrophin, muscle fiber membranes become fragile and susceptible to damage with every contraction. 1

• The membrane instability results in excessive calcium entry, muscle fiber necrosis, chronic inflammation, and progressive fibrotic replacement of muscle tissue. 2 This ongoing muscle breakdown releases massive amounts of CK continuously into the circulation.

Diagnostic Use of CK

CK Level Characteristics in DMD

In DMD patients, CK concentration is usually >10,000 U/L and these levels remain permanently high, not showing temporary fluctuations associated with exercise. 3

Key diagnostic features:

• The highest CK levels are typically seen between 3-5 years of age (average: 27,750-31,173 U/L), after which levels decrease with clinical progression at a yearly average rate of decline of 8.7%. 4

• CK levels in DMD remain permanently elevated and do not normalize within 24-120 hours like exercise-induced elevations in healthy individuals (which can reach >3,000 U/L but return to normal). 3

• The presence of elevated aldolase, particularly aldolase A, in combination with elevated CK strongly supports the diagnosis of primary muscle disease. 1

Diagnostic Algorithm

Proceed directly to genetic testing for dystrophin gene deletions/duplications from a blood sample, as this is always necessary even if muscle biopsy is performed. 3

The testing sequence:

1. First-line genetic testing should include PCR multiplex, multiplex ligation-dependent probe amplification (MLPA), and single-condition amplification/internal hybridization, which detect approximately 95% of DMD mutations. 1, 2

2. If standard deletion/duplication analysis is negative, complete sequencing of the dystrophin gene should be performed to detect point mutations or small insertions/deletions that account for the remaining 5% of cases. 1, 2

3. If genetic testing is negative, muscle biopsy is necessary to evaluate dystrophin protein expression through immunocytochemistry and immunoblotting. 5, 3 The absence of dystrophin protein on muscle biopsy is sufficient to confirm the diagnosis of dystrophinopathy, regardless of genetic test results. 1

4. Full characterization of the mutation is required to correlate the predicted effect on the reading frame, which determines disease progression and eligibility for mutation-specific therapies. 3

Age-Specific Diagnostic Considerations

In children less than 5 years of age, a normal muscle examination cannot completely exclude DMD, but a boy older than 10 years with normal muscle function is highly unlikely to have DMD. 5, 3

Clinical triggers for testing:

• The presence of Gowers' sign in a male child should trigger diagnostic investigation of DMD, especially if the child also has a waddling gait. 5

• Unexplained elevated transaminases (AST/ALT) in a male child are a classic presentation of DMD because these enzymes are produced by both liver and muscle cells. 1, 2

• Delayed walking (>16-18 months), frequent falls, or difficulty running or climbing stairs should prompt CK testing. 2

Monitoring Use of CK

Limitations for Disease Monitoring

While CK is essential for diagnosis, its utility for monitoring disease progression is limited because levels naturally decline with age and muscle loss, making it an unreliable marker of treatment response or disease activity. 4

Instead of CK monitoring:

• Regular evaluations of disease progression should include manual muscle testing (MRC scale) or quantitative myometry, goniometry for range of motion, and standardized timed function tests. 5, 2

• Clinical visits should occur every 6 months, with specialized physical and occupational therapy evaluations every 4 months. 2

Common Pitfalls to Avoid

Do not attribute high CK levels in young boys to "only exercise effect"—in DMD, CK remains permanently high and does not normalize after rest. 3

• If CK levels are fluctuating, re-measure after at least 48-72 hours of rest to distinguish DMD from exercise-induced elevation. 3

• In healthy individuals, maximal exercise can increase CK to >3,000 U/L, but this returns to normal within 24-120 hours, unlike the persistent elevation in DMD. 3

• Consider Becker muscular dystrophy when CK levels are lower than expected for DMD and the clinical picture shows slower progression. 1

Clinical Implications of Early Diagnosis

Early diagnosis allows for timely initiation of glucocorticoid treatment (typically started between 4-6 years of age when motor skills plateau or decline), which can slow disease progression and improve outcomes. 3, 1, 2

Additional benefits:

• Genetic counseling should be provided to the family, with carrier testing offered to all female family members at risk, including mothers and sisters. 1, 2

• Multidisciplinary follow-up with neurologist, physiotherapist, cardiologist, and respiratory specialist is necessary, as cardiomyopathy has become an increasingly important source of morbidity and mortality with improved respiratory support. 3, 2

• Newborn screening incorporating CK analysis may enable children to commence workup in infancy rather than at the current average age of 4.9 years. 6